Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enoxaparin for Preventing RAO After Transradial HAIC
NCT06293287Phase 2Recruiting
- Sponsor
- Zhongshan Hospital (Xiamen), Fudan University
- Start
- Jan 2024
- Primary completion
- Nov 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in Radial artery occlusion (RAO) comparing Enoxaparin with Placebo (2 arms). Primary endpoint: Radial Artery Occlusion rate at 21 days. Started Jan 2024; status: recruiting.
02
Drugs
enoxaparin
03
Conditions
Radial artery occlusion (RAO)
Beyond the preview
Go deeper on NCT06293287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06293287.